T he annual incidence of venous thromboembolism (VTE) in the United States is about 100 per 100,000, which translates into a 30-day mortality rate of 5% to 10%. [1] [2] [3] Studies have suggested there is higher risk of VTE in hospitalized patients with inflammatory bowel disease (IBD). [4] [5] [6] [7] [8] Several acquired and genetic factors have been hypothesized to contribute to VTE development in patients with IBD. [9] [10] [11] Inflammatory process, prolonged immobilization, central venous catheters, and fluid depletion and dehydration are some of the acquired risk factors. Genetic factors that play a role in the occurrence of VTE may be more significant during remission or less active phases of inflammation. 12 Patients with IBD are prone to Clostridium difficile infection (CDI) with a more severe course of disease compared with the non-IBD population. 13 Patients with CDI are more likely to require hospital admission and have higher morbidity and mortality. 14 Although there have been studies highlighting CDI's profound impact on mortality and different comorbidities, its impact on VTE risk in patients with IBD is less known. It is also important to note that CDI is one of the most common causative pathogens for hospital-acquired infections that lead to acute morbidity and mortality. 15 Recently published reports suggest that rates of CDI are rising among patients with IBD and contribute to an increased rate of hospitalization and mortality. 16, 17 IBD itself has been shown to be a specific risk factor for the development of CDI, particularly in those with ulcerative colitis (UC). 16 Rates of both CDI and VTE are higher in patients with IBD. However, no studies have evaluated the impact of CDI on the overall risk of VTE in IBD population. In this study, we assessed the prevalence of VTE in patients with IBD with CDI and compared to those without CDI.
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METHODS

Data Source
Data were obtained from the year 2011 of the Nationwide Inpatient Sample (NIS), which is a part of the Healthcare Cost and Utilization Project sponsored by the Agency for Healthcare Research and Quality. It is the largest all-payer inpatient care database publicly available in the United States and a 20%-stratified sample of U.S. community hospitals. 18 Each hospitalization is treated as an individual entry in the database. There are 15 to 25 diagnoses and 15 procedural diagnoses associated with each hospitalization. Both hospital and discharge weights are provided to facilitate the production of national estimates.
Study Population
The International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes were used to identify adult patients $18 years of age admitted with IBD. Crohn's disease (CD) and UC were identified by ICD-9-CM codes 555.xx and 556.xx, respectively. Patients who were coded for both CD and UC were excluded (weighted N ¼ 976) from the study. Included patients were divided into 2 groups based on the presence or absence of CDI (ICD-9-CM code: 008.45). More specific details of ICD-9-CM codes are shown in Table 1 , Supplemental Digital Content 1, http://links. lww.com/IBD/B602.
Rates of VTE, including deep vein thrombosis and pulmonary embolism, in groups with IBD only or IBD with concomitant CDI were analyzed using univariate and multivariate logistic regression. Charlson comorbidity index was used for assessing the burden of comorbid diseases, which includes 17 distinct conditions, with a higher composite score representing greater comorbidity and vice versa. 19 We used Deyo's modification of the Charlson coding algorithm to measure Charlson comorbidity index, which has been well validated in the administrative data. 20 
Statistical Methods
All categorical variables are presented as weighted percentages. Age, a continuous variable, was converted into categorical variables. Chi-square test was used to compare categorical variables. Continuous variables like length of stay and hospital charges are presented as mean with standard error and were compared using t test. We used the propensityscoring matching method to control for imbalances of patient clinical characteristics between 2 groups (IBD and IBD with CDI) that may have an impact on the prevalence of VTE. A propensity score was assigned to each patient based on the probability of having VTE, which was based on a multivariate logistic regression model that examined the impact of all the clinical characteristics (age category, sex, race, insurance status, Charlson comorbidity index, various risk factors for VTE, and procedures/surgeries/complications from IBD). Patients in the 2 groups with similar propensity score were matched in a 1:1 scheme without replacement using greedy algorithm (i. e., propensity score nearest-neighbor paired matching without replacement). As a result, the 2 groups had similar baseline demographic and clinical characteristics (P . 0.05) after propensity-score greedy matching.
When analyzing VTE outcomes, we calculated the odds ratios (ORs) and 95% confidence intervals (CIs). In addition to univariate analysis, a multivariate logistic regression analysis was performed with adjustment for all demographics, various comorbidities, and procedures/surgeries. We performed all statistical analyses using SAS Version 9.4 (SAS Institute, Cary, NC). All statistical tests were 2-sided with a 0.05 significance level. Because the database is publically available and has deidentified data, this study was deemed exempt by our institutional review board (http://www.mcw.edu/hrpp/InvestigatorsandStudyStaff/NewStudies/Public-Data-Sets.htme). Table 1 shows the baseline characteristics between patients with IBD with CDI versus patients with IBD without CDI. The 2 groups significantly differed in age category (older people [age $61 yr] more in IBD with CDI group), sex (more female in IBD with CDI group), racial distribution, primary insurance payer, IBD type (more UC in IBD with CDI group), and Charlson comorbidity index (those with scores $3 more in IBD with CDI group). The 2 groups also differed in terms of cigarette smoking status, obesity, parenteral nutrition, intubation/mechanical ventilation, and intestinal surgery.
RESULTS
Baseline Characteristics
After propensity-score matching (Table 1) , there were no differences in the 2 groups in terms of age, sex, race, primary insurance payer, IBD type, Charlson comorbidity index, risk factors for VTE (e.g., smoking, obesity, hypercoagulable state, previous history of VTE), and different procedures/surgeries (P . 0.05).
Association with VTE
Of the total 312,147 patients (weighted for national estimate) with discharge diagnosis of IBD, 12,560 (4%) had CDI. The frequency of VTE was 6% in the group with CDI versus 3% in the group without CDI (P , 0.001) ( Table 2) . On multivariate analysis before propensity-score matching, there was increased association of VTE in the CDI group (adjusted OR 1.6, 95% CI 1.4-2.0, P , 0.001). After propensity-score matching, 12,390 patients (unweighted N ¼ 2591) with CDI matched with 12,418 patients (unweighted N ¼ 2591) without CDI were included. Subsequent multivariate analysis showed a persistent association of VTE in the group with CDI (adjusted OR 1.7, 95% CI, 1.4-2.2, P , 0.001) ( Table 2) . We also validated our findings in an independent analysis using NIS 2012 data, which on propensity-score matching resulted in 13,055 IBD hospitalizations which matched with the same number (13, 055) of IBD hospitalizations with CDI. The association of VTE with CDI was significant both on univariate (OR 1.5, 95% CI, 1.2-2.0, P ¼ 0.003) and multivariate analysis (adjusted OR 1.5, 95% CI, 1.2-2.1, P ¼ 0.003) in the matched sample.
Subgroup Analysis
On subgroup analysis performed in the matched sample, CD with CDI had 2.5-fold higher association with VTE as compared to CD without CDI (adjusted OR 2.5, 95% CI, 1.5-4.0, P , 0.001) ( Table 3) , whereas UC with CDI had 1.5-fold higher association as compared to UC without CDI (adjusted OR 1.5, 95% CI, 1.1-2.0, Table 3 ). There was no significant difference in the risk of VTE between CD with CDI versus UC with CDI on multivariate analysis (adjusted OR 1.2, 95% CI, 0.8-1.7, P ¼ 0.4) ( Table 3) .
VTE-related Hospital Outcomes
Mean Hospital Charges VTE-related hospital charges in patients with IBD were higher in those with CDI than without ($211,487 6 22,437 versus $85,446 6 5252, P , 0.001) in the unmatched sample. A similar finding was obtained in the matched sample ($205,532 6 21,238) versus ($115,156 6 12,051, P , 0.001). Even after adjusting for length of stay, hospital charges remained higher in patients with CDI. (Table 4) . Mortality VTE-related mortality in patients with IBD was 16% in those with CDI versus 5% in those without CDI (OR 3.5, 95% CI, 2.2-5.7, P , 0.001). When patients were matched for patient characteristics, however, VTE-related mortality became similar between the 2 groups (Table 4) .
DISCUSSION
Using the NIS database, our study showed significant association between CDI and VTE in patients with IBD. There is almost a 2-fold higher association of VTE in patients with IBD and CDI as compared to those patients without CDI, resulting in increased length of stay and hospital charges. This level of increased VTE risk with IBD is similar to other populations. A recent retrospective cohort study of patients admitted to the surgical intensive care unit also found that patients with CDI had a 2-fold higher risk for the development of VTE. 21 The positive association between infections and risk of VTE has been shown in several other reports. In a populationbased study conducted in Denmark, the adjusted incidence rate ratio for VTE was 3.3 (95% CI, 2.9-3.8) for patients with hospital-diagnosed infection and 2.6 (95% CI, 2.5-2.8) for patients treated with antibiotics in the community, respectively, as compared to subjects with no infections. 22 A French case-control study, which studied 636 patients with deep vein thrombosis diagnosed from 1990 to 1991, found that the adjusted odds for deep vein thrombosis among patients with infectious disease were 1.95 fold (95% CI, 1.31-2.92) compared to those without infection. 23 Inflammation plays a major role in the development of thromboembolic events. Compared to non-IBD subjects, patients with IBD are at a 3-to 4-fold increased risk of VTE. 5, 24 This increased risk is more prominent during IBD flare. 25 The degree of inflammation is increased significantly during CDI, which may account for the increased VTE risk. 26 Toxins A and B in C. difficile colitis are well known to elicit an upregulation of proinflammatory mediators from the lamina propria, leading to a massive neutrophilic infiltration and inflammatory debris. 27 Toxemia has been associated with elevated levels of interleukin-8 in a piglet infection model of acute and chronic CDI, and has been associated with increased risk of VTE. 28, 29 Our study is one of the largest that reports the prevalence of VTE in patients with IBD infected with CDI. We did not find a difference in VTE rates between patients with CD and UC. However, other studies showed differences between the IBD subtypes. A Canadian population-based study of hospitalized patients with IBD highlighted a slightly higher burden of deep venous thrombosis and pulmonary embolism in CD. 5 However, a large American population-based study of hospitalized patients with IBD suggested that VTE was more prevalent among patients with UC compared to CD (OR, 1.32; 95% CI, 1.17-1.48). 7 There are several limitations of our study, including its retrospective nature and the use of ICD-9-CM codes for the diagnosis of IBD and VTE. Medications are not listed in the NIS and thus we could not determine whether the use of prophylactic anticoagulation or IBD treatment differed between patients with and without CDI. Diagnostic codes also do not allow timing to be determined, so it is possible that the VTE event occurred before CDI diagnosis. At last, the NIS documents isolated admissions as opposed to isolated patients; thus it is possible that patients admitted multiple times may be counted as multiple events in our study. Furthermore, inherent to the NIS database is the inability to identify readmissions. We, therefore, were not able to identify readmission rates in our study.
In conclusion, our study from a large nationwide inpatient database shows that patients with IBD with CDI have increased rates of VTE and also have worse VTE-related hospital outcomes. Therefore, effective VTE prophylaxis is warranted to prevent the higher morbidity and mortality in this patient population. Since VTE prophylaxis is the standard-of-care for hospitalized patients with IBD , additional ways to prevent/treat VTE and different approaches to counteract CDI in IBD population should be explored to minimize the risk of VTE.
